[
    [
        {
            "time": "",
            "original_text": "医药生物行业双周报：行业估值处于历史平均以下，择优布局优质标的",
            "features": {
                "keywords": [
                    "医药生物",
                    "行业估值",
                    "历史平均",
                    "优质标的"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药生物行业双周报：行业估值处于历史平均以下，择优布局优质标的",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "三叶草生物通过上市聆讯：两年半亏损19亿，高瓴为第一大机构股东 亏损",
            "features": {
                "keywords": [
                    "三叶草生物",
                    "上市聆讯",
                    "亏损",
                    "高瓴资本"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "三叶草生物通过上市聆讯：两年半亏损19亿，高瓴为第一大机构股东 亏损",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "新冠疫苗加强针陆续开打 记者调查：国药疫苗供应足 ，康希诺疫苗基层渗透率较低",
            "features": {
                "keywords": [
                    "新冠疫苗",
                    "加强针",
                    "国药疫苗",
                    "康希诺疫苗",
                    "供应",
                    "渗透率"
                ],
                "sentiment_score": 0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "新冠疫苗加强针陆续开打 记者调查：国药疫苗供应足 ，康希诺疫苗基层渗透率较低",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]